Alzheimer’s disease is one of the most pressing health challenges of our time. In 2025, an estimated 7.2 million Americans age 65 and older are living with Alzheimer’s dementia, and Alzheimer’s remains the leading cause of dementia worldwide. Dementia is also recognized as the seventh leading cause of death globally.
For decades, Alzheimer’s was often viewed as an unavoidable consequence of aging. Today, research paints a more hopeful and nuanced picture. Large population studies suggest that a substantial portion of dementia risk can be delayed or reduced through modifiable health and lifestyle factors. The Lancet Commission estimated this proportion at approximately 40% in 2020, and the updated 2024 report suggests it may be closer to 45% when additional risk factors are included. This shift places risk reduction and brain resilience at the center of long-term cognitive health.
Understanding The Roots Of Alzheimer’s
Alzheimer’s disease was traditionally defined by the accumulation of amyloid plaques and tau tangles in the brain. While these features remain important and central to diagnosis, Alzheimer’s is increasingly understood as a multifactorial condition involving brain energy metabolism, vascular health, inflammation, oxidative stress, insulin resistance, toxin and environmental exposures, hormonal shifts, and immune dysregulation, interacting with genetic vulnerability.
The strongest known genetic risk factor for late-onset Alzheimer’s disease is the APOE ε4 allele. Carrying one copy is associated with roughly a two- to three-fold increase in risk, while carrying two copies raises risk substantially. Importantly, APOE-related risk is not destiny. Lifestyle and environmental factors can meaningfully influence how this genetic risk translates into clinical disease over time.
A very small proportion of cases, under one percent, are caused by autosomal dominant mutations in genes such as APP, PSEN1, or PSEN2 and are associated with early-onset familial Alzheimer’s disease. These rare forms are far more genetically determined. For the vast majority of people, modifiable lifestyle and health factors play a central role.
In later life, many individuals show mixed dementia pathology, meaning Alzheimer’s-related changes often coexist with vascular dementia or other neurodegenerative processes. This further reinforces the importance of whole-system risk reduction for brain health.
The First Signs and Why Early Action Matters
Alzheimer’s disease develops gradually, often beginning years or decades before noticeable memory loss. Early changes may include difficulty recalling recent conversations, misplacing items, slowed processing speed, or subtle challenges with planning and organization. As the disease progresses, symptoms may include confusion, mood or personality changes, impaired judgment, and loss of independence.
Advances in early detection are improving our ability to identify risk and disease-related changes earlier. Tools such as cognitive testing, structural and functional brain imaging, and emerging blood-based biomarkers, including p-tau217, GFAP, and amyloid ratios, are increasingly used to support risk stratification and diagnostic workups in appropriate clinical settings. These tools are promising, but interpretation is nuanced. A biomarker signal does not automatically predict when, or whether, someone will develop dementia symptoms, particularly in the absence of clinical changes.
Neuroimaging studies examining brain glucose metabolism suggest metabolic changes may precede clinical symptoms, highlighting a window when risk-reduction strategies may be most impactful. Genetic testing for APOE status can also provide useful risk context for some individuals, but results are best interpreted with qualified clinical guidance.
Lifestyle Medicine and Alzheimer’s Risk
Some dementia risk factors are not modifiable, including age, genetics, and conditions such as Down syndrome. However, many influential risk factors can be modified, including cardiovascular and metabolic health, physical activity, sleep quality, hearing loss, vision loss, high LDL cholesterol, mental health, social engagement, education, toxin exposure, and head injury. Lifestyle medicine addresses these interconnected systems to support brain resilience across the lifespan.
For some individuals, targeted clinical and laboratory evaluation can help clarify metabolic, vascular, nutritional, or sleep-related risk factors and guide more personalized prevention strategies.
Nutrition
Diet plays a foundational role in brain health. The MIND diet, which combines elements of Mediterranean and DASH dietary patterns, has been consistently associated with substantially lower Alzheimer’s risk in observational research. Higher adherence is linked with greater protection, and even moderate adherence appears to confer measurable benefit.
Mediterranean-style eating patterns rich in vegetables, fruits, legumes, whole grains, olive oil, and fatty fish are also associated with reduced cognitive decline and dementia risk. Emerging research suggests dietary patterns may help mitigate genetic vulnerability, including in some APOE ε4 carriers. Beyond named diets, metabolic and vascular support through fiber-rich, minimally processed foods can reduce inflammation and support long-term cognitive vitality.
Movement
Regular physical activity improves cerebral blood flow, reduces vascular risk, and supports neuroplasticity. Exercise is associated with increased brain-derived neurotrophic factor (BDNF), a key protein involved in synaptic strength, learning, and memory. Aerobic activity shows the most consistent effects on BDNF in human studies, while resistance training contributes meaningfully through metabolic and vascular benefits.
Even moderate, regular movement such as brisk walking is associated with better cognitive outcomes. Physical activity also protects the brain indirectly by improving insulin sensitivity, lowering blood pressure, and reducing systemic inflammation.
Sleep
Sleep is essential for brain maintenance and repair. During sleep, the brain’s glymphatic system becomes more active, supporting the clearance of metabolic waste products, including amyloid beta. Sleep disruption is associated with impaired clearance and greater amyloid burden over time.
Experimental studies suggest that even short-term sleep restriction can increase amyloid-related signals in specific brain regions, and chronic sleep disruption is linked to faster cognitive decline. Prioritizing consistent, restorative sleep is widely regarded as one of the most impactful lifestyle strategies for long-term brain health.
Stress Management
Chronic stress is associated with sustained cortisol exposure and changes in hippocampal structure and function, a brain region critical for memory and emotional regulation. Long-term stress is linked to poorer cognitive performance and increased vulnerability to neurodegenerative processes.
Practices such as mindfulness, meditation, breathwork, yoga, tai chi, time in nature, and expressive writing can support nervous system regulation and stress resilience. No single technique is sufficient on its own, but regular practice over time appears to matter most.
Social Connection And Brain Health
Loneliness and social isolation are recognized risk factors for cognitive decline and dementia, including Alzheimer’s disease. Longitudinal studies show that people with stronger social networks tend to have better cognitive outcomes, healthier lifestyle patterns, and lower stress physiology.
While the relationship is likely bidirectional, maintaining relationships, volunteering, and meaningful community engagement are consistently associated with better cognitive and emotional health and may help reduce dementia risk over time.
Cognitive Engagement And Cognitive Reserve
Lifelong learning helps build cognitive reserve, the brain’s ability to maintain function despite age-related or disease-related changes. Activities that involve novelty, complexity, and sustained mental effort such as learning new skills, music, problem solving, reading, or continuing education strengthen neural networks and adaptability over time.
Cognitive reserve does not prevent underlying brain pathology, but it can delay the onset of symptoms and support brain resilience for longer, even as age- or disease-related changes accumulate.
Individualized Targeted Support
Lifestyle strategies form the foundation of Alzheimer’s risk reduction, but for many individuals, targeted nutritional and metabolic support can meaningfully strengthen that foundation.
Nutrients such as B vitamins, vitamin D, omega-3 fatty acids, magnesium, zinc, and vitamin E play essential roles in brain energy metabolism, vascular function, neurotransmitter balance, and inflammatory regulation. Clinical and population studies suggest that correcting deficiencies or addressing specific risk profiles may support cognitive performance and brain resilience, particularly in midlife and early older age.
Supplementation is not a one-size-fits-all solution. When used strategically and appropriately, it can help close common nutritional gaps created by modern diets, chronic stress, and metabolic strain. This is where individualized assessment and clinical context matters most.
Evidence for additional compounds such as coenzyme Q10, curcumin, creatine, lion’s mane mushroom, acetyl-L-carnitine, and NAD⁺ precursors is emerging, with early human data and strong mechanistic rationale in specific contexts. In practice, these compounds are best used as adjuncts to lifestyle and medical care, not as standalone interventions or guarantees of prevention.
In women, the menopausal transition is an important window for brain health. When clinically appropriate and appropriately timed, hormone therapy may influence cognitive trajectories for some individuals. Decisions should be individualized, taking into account personal risk factors, timing, formulation, and overall health goals.
The Future of Treatment
Current medications may slow disease progression in select patients with early Alzheimer’s disease, but they do not reverse established neurodegeneration or restore lost brain function. While newer therapies can modify certain biological markers of the disease, risk reduction and early intervention remain the most broadly accessible and impactful strategies across the population.
Multidomain lifestyle-based programs integrating nutrition, physical activity, sleep, stress regulation, and metabolic health reflect growing recognition that brain health is shaped by daily choices that influence metabolism, vascular integrity, inflammation, and neural plasticity.
When supplementation is appropriate, I prioritize evidence-based, third-party tested options that complement lifestyle medicine rather than replace it.
Your Brain, Your Future
Alzheimer’s disease is not determined by age or genetics alone. Lifestyle patterns established over decades play a powerful role in shaping brain resilience and long-term cognitive health.
By prioritizing nutrition, movement, sleep, stress regulation, cognitive engagement, and social connection, many people can meaningfully reduce risk and support lifelong cognitive vitality.
At Dr. Gogol Health & Wellness, my mission is to empower you with science-based tools that help you care for your brain across every stage of life.
Start small. Stay consistent. Protect your brain for life.
If this information resonates with you, I invite you to subscribe. You’ll receive evidence-based insights and practical tools to support brain health, cognitive vitality, and long-term wellness.
If you’re looking for more personalized guidance, you can explore lifestyle coaching and educational support through Dr. Gogol Health & Wellness, where we focus on building sustainable habits that support brain and metabolic health over time.
You can also explore the Dr. Gogol Health & Wellness Store, including thoughtfully curated cognitive support options designed to complement a strong lifestyle foundation.
Key Takeaways
• Alzheimer’s risk is influenced by genetics, but lifestyle and health factors meaningfully shape brain resilience
• A substantial portion of dementia risk may be delayed or reduced through modifiable factors
• Alzheimer’s develops gradually, often years before obvious memory loss, so early action matters
• Multidomain lifestyle approaches support brain health across metabolic, vascular, inflammatory, and stress-related pathways
• Small, consistent habits tend to outperform all-or-nothing changes
Frequently Asked Questions About Alzheimer’s Risk and Prevention
Can Alzheimer’s be prevented or delayed?
Most experts frame this as delaying onset and reducing risk rather than guaranteeing prevention. Addressing modifiable risk factors across the lifespan may meaningfully lower dementia risk and delay symptoms for many people.
What are the earliest signs of Alzheimer’s?
Early signs can include repeating questions, difficulty recalling recent conversations, misplacing items, word-finding difficulty, challenges with planning or organization, and subtle changes in judgment or mood.
What lifestyle changes reduce dementia risk the most?
The strongest evidence supports a whole-system approach including cardiovascular and metabolic health, regular physical activity, high-quality sleep, hearing care, stress regulation, social connection, cognitive engagement, avoiding smoking, limiting excess alcohol, and preventing head injury.
Should I get APOE genetic testing?
APOE testing can be helpful in select cases but may also increase anxiety without changing day-to-day recommendations. Testing is best considered with qualified clinical guidance.
Are blood tests for Alzheimer’s accurate?
Blood-based biomarkers such as p-tau217 and amyloid-beta ratios are advancing rapidly and can aid clinical evaluation, especially when symptoms are present. Interpretation is nuanced, and these tests are best used as part of an individualized medical workup.
Medical Disclaimer:
This content is for educational purposes only and is not intended to replace individualized medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your health, supplements, or medications.
Lynette Gogol, DO, DipABLM
Neurologist & Lifestyle Medicine Physician
Last updated: February 6, 2026
Scientific References
Alzheimer’s Association. (2024). 2024 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 20(3), 1–128. https://doi.org/10.1002/alz.13809
Alzheimer’s Association. (2025, August 4). Food for thought. Alzheimer’s Association. https://www.alz.org/news/2019/food-for-thought
Bredesen, D. E. (2025). The Ageless Brain. Flatiron Books.
Bredesen, D. E. (2014). Reversal of cognitive decline: A novel therapeutic program. Aging, 6(9), 707–717. https://doi.org/10.18632/aging.100690
Carroll, J. C., Rosario, E. R., Chang, L., Stanczyk, F. Z., Oddo, S., LaFerla, F. M., & Pike, C. J. (2007). Progesterone and estrogen regulate Alzheimer-Like neuropathology in female 3xTG-AD mice. Journal of Neuroscience, 27(48), 13357–13365. https://doi.org/10.1523/jneurosci.2718-07.2007
Centers for Disease Control and Prevention (CDC). (2024, August 15). About Alzheimer’s. https://www.cdc.gov/alzheimers-dementia/about/alzheimers.html
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., Prieto, S., Chen, P., Loreck, D. J., Trapp, G., Bakshi, R. S., Mintzer, J. E., Heidebrink, J. L., Vidal-Cardona, A., Arroyo, L. M., Cruz, A. R., … Guarino, P. D. (2014). Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA, 311(1), 33–44. https://doi.org/10.1001/jama.2013.282834
Erickson, K. I., Voss, M. W., Prakash, R. S., Basak, C., Szabo, A., Chaddock, L., Kim, J. S., Heo, S., Alves, H., White, S. M., Wojcicki, T. R., Mailey, E., Vieira, V. J., Martin, S. A., Pence, B. D., Woods, J. A., McAuley, E., & Kramer, A. F. (2011). Exercise training increases size of hippocampus and improves memory. Proceedings of the National Academy of Sciences of the United States of America, 108(7), 3017–3022. https://doi.org/10.1073/pnas.1015950108
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., Myers, R. H., Pericak-Vance, M. A., Risch, N., & van Duijn, C. M. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 278(16), 1349–1356.
Fekete, M., Varga, P., Ungvari, Z., Fekete, J. T., Buda, A., Szappanos, Á., Lehoczki, A., Mózes, N., Grosso, G., Godos, J., Menyhart, O., Munkácsy, G., Tarantini, S., Yabluchanskiy, A., Ungvari, A., & Győrffy, B. (2025). The role of the Mediterranean diet in reducing the risk of cognitive impairement, dementia, and Alzheimer’s disease: a meta-analysis. GeroScience, 47(3), 3111–3130. https://doi.org/10.1007/s11357-024-01488-3
Guarnera, J., Yuen, E., & Macpherson, H. (2023). The Impact of Loneliness and Social Isolation on Cognitive Aging: A Narrative Review. Journal of Alzheimer’s disease reports, 7(1), 699–714. https://doi.org/10.3233/ADR-230011
Hansson, O. (2021). Biomarkers for neurodegenerative diseases. Nature Medicine, 27, 954–963. https://doi.org/10.1038/s41591-021-01382-x
Holwerda, T. J., Deeg, D. J., Beekman, A. T., van Tilburg, T. G., Stek, M. L., Jonker, C., & Schoevers, R. A. (2014). Feelings of loneliness, but not social isolation, predict dementia onset: results from the Amsterdam Study of the Elderly (AMSTEL). Journal of neurology, neurosurgery, and psychiatry, 85(2), 135–142. https://doi.org/10.1136/jnnp-2012-302755
Ju, Y. E., Lucey, B. P., & Holtzman, D. M. (2014). Sleep and Alzheimer disease pathology–a bidirectional relationship. Nature reviews. Neurology, 10(2), 115–119. https://doi.org/10.1038/nrneurol.2013.269
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Ogunniyi, A., Orgeta, V., … Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet (London, England), 396(10248), 413–446. https://doi.org/10.1016/S0140-6736(20)30367-6
Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, Ames D, Banerjee S, Burns A, Brayne C, Fox NC, Ferri CP, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Nakasujja N, Rockwood K, Samus Q, Shirai K, Singh-Manoux A, Schneider LS, Walsh S, Yao Y, Sommerlad A, Mukadam N. (2024) Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01296-0/abstract
Liu, Y., Gu, X., Li, Y., Wang, F., Vyas, C. M., Peng, C., Dong, D., Li, Y., Zhang, Y., Zhang, Y., Zeleznik, O. A., Kang, J. H., Wang, M., Hu, F. B., Willett, W. C., Okereke, O. I., Eliassen, A. H., Kraft, P., Stampfer, M. J., & Wang, D. D. (2025). Interplay of genetic predisposition, plasma metabolome and Mediterranean diet in dementia risk and cognitive function. Nature Medicine. https://doi.org/10.1038/s41591-025-03891-5
Lupien, S. J., McEwen, B. S., Gunnar, M. R., & Heim, C. (2009). Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nature reviews. Neuroscience, 10(6), 434–445. https://doi.org/10.1038/nrn2639
Morris, M. C., Tangney, C. C., Wang, Y., Sacks, F. M., Bennett, D. A., & Aggarwal, N. T. (2015). MIND diet associated with reduced incidence of Alzheimer’s disease. Alzheimer’s & dementia : the journal of the Alzheimer’s Association, 11(9), 1007–1014. https://doi.org/10.1016/j.jalz.2014.11.009
Mosconi, L. (2018). Brain Food: The Surprising Science of Eating for Cognitive Power. Avery.
Mosconi, L. (2013). Glucose metabolism in normal aging and Alzheimer’s disease: Methodological and physiological considerations for PET studies. Clinical and Translational Imaging, 1, 217-233. https://doi.org/10.1007/s40336-013-0026-y
Saitsu, Y., Nishide, A., Kikushima, K., Shimizu, K., & Ohnuki, K. (2019). Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomedical research (Tokyo, Japan), 40(4), 125–131. https://doi.org/10.2220/biomedres.40.125
Scott, E., Zhang, Q., Wang, R., Vadlamudi, R., & Brann, D. (2011b). Estrogen neuroprotection and the critical period hypothesis. Frontiers in Neuroendocrinology, 33(1), 85–104. https://doi.org/10.1016/j.yfrne.2011.10.001
Shokri-Kojori, E., Wang, G. J., Wiers, C. E., Demiral, S. B., Guo, M., Kim, S. W., Lindgren, E., Ramirez, V., Zehra, A., Freeman, C., Miller, G., Manza, P., Srivastava, T., De Santi, S., Tomasi, D., Benveniste, H., & Volkow, N. D. (2018). β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proceedings of the National Academy of Sciences of the United States of America, 115(17), 4483–4488. https://doi.org/10.1073/pnas.1721694115
Smith, A. D., et al. (2010). Homocysteine-lowering by B vitamins slows brain atrophy in people with MCI. PLoS One, 5(9), e12244. https://doi.org/10.1371/journal.pone.0012244
Stern Y. (2012). Cognitive reserve in ageing and Alzheimer’s disease. The Lancet. Neurology, 11(11), 1006–1012. https://doi.org/10.1016/S1474-4422(12)70191-6
Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in Early Alzheimer’s Disease. The New England journal of medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
Voss, M. W., Vivar, C., Kramer, A. F., & van Praag, H. (2013). Bridging animal and human models of exercise-induced brain plasticity. Trends in cognitive sciences, 17(10), 525–544. https://doi.org/10.1016/j.tics.2013.08.001
Wayne, P. M., Walsh, J. N., Taylor-Piliae, R. E., Wells, R. E., Papp, K. V., Donovan, N. J., & Yeh, G. Y. (2014). Effect of tai chi on cognitive performance in older adults: systematic review and meta-analysis. Journal of the American Geriatrics Society, 62(1), 25–39. https://doi.org/10.1111/jgs.12611
Whitmer, R. A., Quesenberry, C. P., Zhou, J., & Yaffe, K. (2011). Timing of hormone therapy and dementia: the critical window theory revisited. Annals of neurology, 69(1), 163–169. https://doi.org/10.1002/ana.22239
Wilson, R. S., Arnold, S. E., Schneider, J. A., Li, Y., & Bennett, D. A. (2007). Chronic distress, age-related neuropathology, and late-life dementia. Psychosomatic medicine, 69(1), 47–53. https://doi.org/10.1097/01.psy.0000250264.25017.21
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., Takano, T., Deane, R., & Nedergaard, M. (2013). Sleep drives metabolite clearance from the adult brain. Science (New York, N.Y.), 342(6156), 373–377. https://doi.org/10.1126/science.1241224 Yurko-Mauro, K., et al. (2010). Beneficial effects of docosahexaenoic acid on cognition in age-related decline. Alzheimer’s & Dementia, 6(6), 456–464. https://doi.org/10.1016/j.jalz.2010.01.013
